GSK, Genmab adopt new development strategy for ofatumumab

Faced with stiff and growing competition in the autoimmune arena, Genmab and GlaxoSmithKline are tossing out their planned development program for an intravenous formulation of ofatumumab in favor of a more easily administered injectable.

Ofatumumab is approved to treat leukemia under the name Arzerra. But the biopharma companies are also teamed on developing a new formulation for big market diseases like rheumatoid arthritis and multiple sclerosis--two indications that are getting close attention in the drug development world.

"Although the intravenous delivery of ofatumumab has previously demonstrated positive results in MS and RA studies, the autoimmune program is being refocused on the subcutaneous delivery of ofatumumab because GSK believes this route of administration has the potential to offer added convenience and improved tolerability" says Ian Tomlinson, GSK's SVP Biopharmaceuticals R&D.

The collaboration between Genmab and GlaxoSmithKline has undergone several changes this year. In July, the two companies agreed that GSK would be solely responsible for developing ofatumumab for autoimmune indications while they continued to work together in oncology.

- here's the Genmab release
- see the Reuters report

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.